Verona Pharma plc (NASDAQ:TARA) has been given a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Verona Pharma’s rating score has improved by 14.2% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 12-month consensus price target of $45.00 for the company, according to Zacks. Zacks has also given Verona Pharma an industry rank of 80 out of 255 based on the ratings given to its competitors.
Several research firms have recently issued reports on TARA. ValuEngine raised Verona Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. LADENBURG THALM/SH SH began coverage on Verona Pharma in a research note on Wednesday, January 22nd. They issued a “buy” rating and a $45.00 price objective for the company.
A hedge fund recently bought a new stake in Verona Pharma stock. Victory Capital Management Inc. bought a new stake in shares of Verona Pharma plc (NASDAQ:TARA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 992 shares of the company’s stock, valued at approximately $32,000. Victory Capital Management Inc. owned 0.18% of Verona Pharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 36.90% of the company’s stock.
About Verona Pharma
ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.
Recommended Story: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.